 |
|
|
| |
Bictegravir Dissociation Half-life from HIV-1
G140S/Q148H Integrase-DNA Complexes
|
| |
| |
Reported by Jules Levin
CROI 2017 Feb 14-16 Seattle, WA
Kirsten White*, Anita Niedziela-Majka, Nikolai Novikov, Michael Miller, Haolun Jin, Scott Lazerwith, and Manuel Tsiang
Gilead Sciences, Foster City, CA
Download the PDF here
CROI: Randomized Trial of Bictegravir or Dolutegravir with FTC/TAF for Initial HIV Therapy - (02/16/17)
Webcast:http://www.croiwebcasts.org/console/player/33378?mediaType=slideVideo&
ASM June 2016 / CROI: Clinical Pharmacology of the Unboosted HIV Integrase Strand Transfer Inhibitor (INSTI) Bictegravir (BIC) - (02/16/17)
WEBCAST:http://www.croiwebcasts.org/console/player/33377?mediaType=slideVideo&
Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile....
http://aac.asm.org/content/60/12/7086.full?sid=1760f614-1eea-45c9-94aa-27af3440669b
Pdf attached above
|
| |
|
|
|
|
|
